JP2789134B2 - 糖尿病の合併症を制御する置換ピリミジン類 - Google Patents

糖尿病の合併症を制御する置換ピリミジン類

Info

Publication number
JP2789134B2
JP2789134B2 JP6509004A JP50900494A JP2789134B2 JP 2789134 B2 JP2789134 B2 JP 2789134B2 JP 6509004 A JP6509004 A JP 6509004A JP 50900494 A JP50900494 A JP 50900494A JP 2789134 B2 JP2789134 B2 JP 2789134B2
Authority
JP
Japan
Prior art keywords
alkyl
general formula
compound
hydrogen
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP6509004A
Other languages
English (en)
Japanese (ja)
Other versions
JPH07507072A (ja
Inventor
エル． マイレリ，バナヴァラ
ジェイ． オーツ，ピーター
ダブリュ． シーゲル，トッド
ジェイ． ゼンブロウスキ，ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of JPH07507072A publication Critical patent/JPH07507072A/ja
Application granted granted Critical
Publication of JP2789134B2 publication Critical patent/JP2789134B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP6509004A 1992-09-28 1993-07-12 糖尿病の合併症を制御する置換ピリミジン類 Expired - Fee Related JP2789134B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95222292A 1992-09-28 1992-09-28
US952,222 1992-09-28

Publications (2)

Publication Number Publication Date
JPH07507072A JPH07507072A (ja) 1995-08-03
JP2789134B2 true JP2789134B2 (ja) 1998-08-20

Family

ID=25492671

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6509004A Expired - Fee Related JP2789134B2 (ja) 1992-09-28 1993-07-12 糖尿病の合併症を制御する置換ピリミジン類

Country Status (15)

Country Link
US (2) US5728704A (show.php)
EP (1) EP0662962A1 (show.php)
JP (1) JP2789134B2 (show.php)
KR (1) KR950703539A (show.php)
AU (1) AU683620B2 (show.php)
CA (1) CA2145640C (show.php)
FI (1) FI934224A7 (show.php)
HU (1) HU220669B1 (show.php)
IL (1) IL107085A (show.php)
MY (1) MY115288A (show.php)
NO (1) NO306598B1 (show.php)
NZ (1) NZ254550A (show.php)
TW (1) TW284759B (show.php)
WO (1) WO1994007867A1 (show.php)
ZA (1) ZA937142B (show.php)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2145640C (en) * 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications
DE69408750T2 (de) * 1993-08-26 1998-07-23 Ono Pharmaceutical Co 4-Aminopyrimidin Derivate
GB9325217D0 (en) * 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
ATE216226T1 (de) * 1996-02-29 2002-05-15 Pfizer Verwendung von sorbitol-dehydrogenase-inhibitoren zum reduzieren von ischämie-assozierten gewebeschäden
EP0970095B1 (en) * 1997-03-07 2003-10-29 Metabasis Therapeutics, Inc. Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
EP1402895A1 (en) * 1997-03-07 2004-03-31 Metabasis Therapeutics, Inc. Benzimidazole inhibitors of fructose 1,6-biphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DE19710435A1 (de) * 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
IL158466A0 (en) * 1997-04-15 2004-05-12 Csir Pharmaceutical compositions having appetite suppressant activity
IL124236A (en) * 1997-05-05 2003-01-12 Pfizer Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor
BR9913532A (pt) * 1998-09-09 2001-10-02 Metabasis Therapeutics Inc Novos inibidores heteroaromáticos de frutose 1,6-bifosfatase
CN100349904C (zh) * 1998-09-09 2007-11-21 症变治疗公司 新的果糖1,6－二磷酸酶的杂芳族抑制剂
AU2003242500B2 (en) * 1998-09-09 2006-11-02 Metabasis Therapeutics, Inc. Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
ATE264311T1 (de) 1999-04-01 2004-04-15 Pfizer Prod Inc Verbindungen zur behandlung und vorsorge bei diabetes
TR200102810T2 (tr) * 1999-04-01 2002-01-21 Pfizer Products Inc. Sorbitol dehidrojenaz inhibitörleri olarak aminopirimidinler
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
US6380200B1 (en) * 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
IL149887A0 (en) * 1999-12-22 2002-11-10 Metabasis Therapeutics Inc Novel bisamidate phosphonate prodrugs
US6919322B2 (en) * 2000-03-08 2005-07-19 Metabasis Therapeutics, Inc. Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
KR100611853B1 (ko) * 2000-11-10 2006-08-11 에프. 호프만-라 로슈 아게 피리미딘 유도체 및 이의 신경펩타이드 ｙ 수용체리간드로서의 용도
OA12413A (en) * 2000-11-30 2004-09-30 Pfizer Prod Inc Combination of GABA agonists and aldose reductase inhibitors.
HRP20030420A2 (en) * 2000-11-30 2004-08-31 Pfizer Prod Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
US7081470B2 (en) 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US20040127502A1 (en) * 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression
EP1247809A3 (en) * 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
AU2002341257A1 (en) * 2001-10-15 2003-04-28 Pfizer Products Inc. Three dimensional crystal structure of human sorbitol dehydrogenase and uses thereof
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
JP2005519895A (ja) * 2002-01-18 2005-07-07 ファルマシア・コーポレーション Ｐ３８阻害剤としての置換ピリダジノン
KR20040099324A (ko) 2002-03-13 2004-11-26 유로-셀티큐 에스.에이. 아릴 치환된 피리미딘 및 이것의 용도
WO2004000820A2 (en) * 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
WO2004000318A2 (en) * 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US7083813B2 (en) * 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050261292A1 (en) * 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
CN1997370B (zh) * 2004-05-19 2011-06-01 索尔瓦药物有限公司 N-氨磺酰-n＇-芳基哌嗪类化合物在制备用于预防或治疗肥胖和相关疾病的药物中的用途
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
KR20070053764A (ko) * 2004-08-18 2007-05-25 메타베이시스 테라퓨틱스, 인크. 프럭토스 1,6-비스포스파타제의 신규한 티아졸 억제제들
AU2005286592A1 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
AU2005316739A1 (en) * 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AU2006335967B2 (en) * 2006-01-19 2012-01-19 Orchid Chemicals & Pharmaceuticals Limited Novel heterocycles
US7863446B2 (en) * 2006-01-19 2011-01-04 Orchid Research Laboratories Limited Heterocycles
US8158667B2 (en) * 2006-08-21 2012-04-17 Kador Peter F Topical treatment of cataracts in dogs
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
WO2008110551A1 (en) 2007-03-12 2008-09-18 Zadec Aps An anti-diabetic extract of rooibos
AU2008243874B2 (en) * 2007-04-27 2012-01-19 Purdue Pharma L.P. TRPV1 antagonists and uses thereof
WO2009095773A2 (en) 2008-02-01 2009-08-06 Orchid Research Laboratories Limited Novel heterocycles
US20130072519A1 (en) 2010-05-21 2013-03-21 Edward Lee Conn 2-phenyl benzoylamides
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
JP5699251B2 (ja) 2011-06-22 2015-04-08 パーデュー、ファーマ、リミテッド、パートナーシップ ジヒドロキシ置換基を包含するｔｒｐｖ１アンタゴニストおよびその使用
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EP3352754B1 (en) 2016-06-21 2020-09-02 The Trustees of Columbia University in the City of New York Aldose reductase inhibitors and methods of use thereof
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
CN108101883B (zh) * 2018-01-31 2018-11-13 佳木斯大学附属第一医院 一种用于防治糖尿病视网膜病变的药物及其制备方法
DK3911648T3 (da) 2019-01-18 2025-01-13 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf
BR112021021939A2 (pt) 2019-05-07 2022-02-22 Ucl Business Ltd Tratamento e detecção de neuropatias herdadas e distúrbios associados

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1063014A (fr) * 1950-06-14 1954-04-29 Wellcome Found Dérivés de pyrimidine et leur préparation
GB959699A (en) * 1961-06-09 1964-06-03 May & Baker Ltd New pyrimidine derivatives
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
FR2489141A1 (fr) * 1980-09-03 1982-03-05 Sevifra Appareil chirurgical pour la decoupe precise de la cornee
DOP1981004033A (es) * 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
CA1176269A (en) * 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
US5066659A (en) * 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
US5102908A (en) * 1985-03-15 1992-04-07 Michael Albeck Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
JPH0637473B2 (ja) * 1985-10-11 1994-05-18 三共株式会社 ラクタム化合物
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4835410A (en) * 1988-02-26 1989-05-30 Black & Decker Inc. Dual-mode corded/cordless system for power-operated devices
GB8810203D0 (en) * 1988-04-29 1988-06-02 Ici Plc Heterocyclic compounds
GB8902405D0 (en) * 1989-02-03 1989-03-22 Ici Plc Heterocyclic compounds
DE3905364A1 (de) * 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US5039672A (en) * 1990-04-05 1991-08-13 Pfizer Inc. Heterocyclic compounds as aldose reductase inhibitors
US5098904A (en) * 1990-06-27 1992-03-24 Bristol-Myers Squibb Company Cerebral function enhancing pyrimidinyl derivatives
GB9016984D0 (en) * 1990-08-02 1990-09-19 Ici Plc Aniline derivatives
DE4025387A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien
WO1992004333A1 (fr) * 1990-08-31 1992-03-19 Nippon Shinyaku Co., Ltd. Derive de pyrimidine et medicament
CA2145640C (en) * 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications

Also Published As

Publication number Publication date
TW284759B (show.php) 1996-09-01
HU9302734D0 (en) 1993-12-28
HU220669B1 (hu) 2002-04-29
NO306598B1 (no) 1999-11-29
CA2145640A1 (en) 1994-04-14
KR950703539A (ko) 1995-09-20
ZA937142B (en) 1995-03-23
HUT65531A (en) 1994-06-28
WO1994007867A1 (en) 1994-04-14
AU4669793A (en) 1994-04-26
US5728704A (en) 1998-03-17
AU683620B2 (en) 1997-11-20
EP0662962A1 (en) 1995-07-19
NO951155D0 (no) 1995-03-27
CA2145640C (en) 2001-01-30
IL107085A0 (en) 1993-12-28
FI934224L (fi) 1994-03-29
NZ254550A (en) 1997-08-22
JPH07507072A (ja) 1995-08-03
FI934224A7 (fi) 1994-03-29
NO951155L (no) 1995-05-26
MY115288A (en) 2003-05-31
FI934224A0 (fi) 1993-09-27
US5866578A (en) 1999-02-02
IL107085A (en) 2001-01-11

Similar Documents

Publication Publication Date Title
JP2789134B2 (ja) 糖尿病の合併症を制御する置換ピリミジン類
EP1041068B1 (en) Compounds for treating and preventing diabetic complications
US5594015A (en) Thiazolidine derivatives for the treatment of psoriasis
WO2020146636A1 (en) Compounds and methods for treating or preventing heart failure
US6110951A (en) Thiazolidine derivatives for the treatment of hypertension
JPH09505055A (ja) サイトカイン媒介疾患治療用オキサゾール
JPH10500413A (ja) 新規化合物
JPH06199811A (ja) ジアザ化合物
TWI630204B (zh) 呼吸器官疾病用藥
JP2001518507A (ja) 新規シクロアルケニル置換化合物
AU2106501A (en) Pyrrolidines which inhibit camp-specific pde
JPS5940388B2 (ja) ヒダントイン誘導体治療剤
JP2000507556A (ja) ケモカインのカルボン酸インドール阻害剤
KR20020073176A (ko) 불안증 개선 방법
KR100478798B1 (ko) 4-헤테로사이클릴설폰아미딜-6-메톡시-5-(2-메톡시-페녹시)-2-피리딜-피리미딘 유도체, 그의 제조 방법 및 엔도텔린수용체 길항제로서의 그의 용도
JPH10511978A (ja) アルツハイマー病の治療用薬剤
US20030040531A1 (en) Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist
US20090298745A1 (en) Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
KR20070026551A (ko) 신규한 베타 효능제, 이의 제조방법 및 약제로서의 이의용도
EP0469837B1 (en) Use of a compound in the manufactur of a medicament for lowering of blood uric acid levels
HUT67836A (en) Pyridazinone acetic acids having aldose reductase inhibitory activity, pharmaceutical compositions containing them and process for preparation of them
AU714038B2 (en) Method of reducing tissue damage associated with ischemia
JPH06211814A (ja) （チオ）ウレア誘導体
EP0517877A1 (en) Novel 3(2h)-pyridazinones, pharmaceutical compositions containing them and process for preparing same
MXPA00003243A (en) Compounds for treating and preventing diabetic complications

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees